ZA98418B - Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid - Google Patents

Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid

Info

Publication number
ZA98418B
ZA98418B ZA98418A ZA98418A ZA98418B ZA 98418 B ZA98418 B ZA 98418B ZA 98418 A ZA98418 A ZA 98418A ZA 98418 A ZA98418 A ZA 98418A ZA 98418 B ZA98418 B ZA 98418B
Authority
ZA
South Africa
Prior art keywords
inhibiting
degradation
methods
lewis acid
fluoroether
Prior art date
Application number
ZA98418A
Other languages
English (en)
Inventor
Christopher Bieniarz
Steve H Chang
Keith R Cromack
Shuyen L Huang
Toshikazu Kawai
Manami Kobayashi
David Loffredo
Rajagopalan Raghavan
Earl R Speicher
Honorate A Stelmach
Original Assignee
Abbott Lab
Central Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25148366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA98418(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Central Glass Co Ltd filed Critical Abbott Lab
Publication of ZA98418B publication Critical patent/ZA98418B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Catalysts (AREA)
  • Steroid Compounds (AREA)
ZA98418A 1997-01-27 1998-01-19 Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid ZA98418B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/789,679 US5990176A (en) 1997-01-27 1997-01-27 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

Publications (1)

Publication Number Publication Date
ZA98418B true ZA98418B (en) 1999-04-20

Family

ID=25148366

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA98418A ZA98418B (en) 1997-01-27 1998-01-19 Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid

Country Status (28)

Country Link
US (6) US5990176A (fr)
EP (2) EP0967975B1 (fr)
JP (5) JP3183520B2 (fr)
KR (1) KR100368672B1 (fr)
CN (3) CN1899271A (fr)
AR (2) AR011090A1 (fr)
AT (2) ATE320798T1 (fr)
AU (1) AU726733B2 (fr)
BG (2) BG65414B1 (fr)
BR (1) BR9806996A (fr)
CA (2) CA2626424A1 (fr)
CO (1) CO4920220A1 (fr)
CZ (1) CZ297092B6 (fr)
DE (2) DE69800928T2 (fr)
DK (2) DK1114641T3 (fr)
ES (2) ES2256104T3 (fr)
GR (1) GR3036190T3 (fr)
HK (1) HK1074434A1 (fr)
HU (1) HUP0002101A3 (fr)
IL (1) IL130150A (fr)
NO (1) NO993606L (fr)
NZ (1) NZ335994A (fr)
PL (1) PL334477A1 (fr)
PT (2) PT967975E (fr)
SK (1) SK284243B6 (fr)
TR (1) TR199901579T2 (fr)
WO (1) WO1998032430A1 (fr)
ZA (1) ZA98418B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
US20030200963A1 (en) * 1998-01-09 2003-10-30 Flament-Garcia Mary Jane Container for an inhalation anesthetic
US6074668A (en) * 1998-01-09 2000-06-13 Abbott Laboratories Container for an inhalation anesthetic
US6162443A (en) * 1998-01-09 2000-12-19 Abbott Laboratories Container for an inhalation anesthetic
US7097849B2 (en) * 1998-08-19 2006-08-29 Jagotec Ag Injectable aqueous dispersions of propofol
EP1439677B9 (fr) 1999-01-08 2007-11-07 Sony Deutschland GmbH Structure de symboles synchronisation pour un système MDFO
TW523409B (en) 2000-09-15 2003-03-11 Baxter Int Container for inhalation anesthetic
ES2289524T3 (es) * 2003-09-10 2008-02-01 Cristalia Produtos Quimicos Farmaceuticos Ltda. Composicion farmaceutica estable de un compuesto de fluoroeter para uso anestesico, procedimiento para estabilizar un compuesto de fluoroeter, uso de un agente estabilizador para evitar la degradacion de un compuesto de fluoroeter.
BR0303489A (pt) * 2003-09-10 2005-07-05 Cristalia Prod Quimicos Farm Composição farmacêutica estabilizada de composto flúor-éter e método para inibir a degradação de composto flúor-éter. uso de agente estabilizante para inibir a degradação de composto flúor éter
CA2605246C (fr) * 2005-04-18 2015-11-17 Minrad Inc. Preparation de sevoflurane avec un contenu en eau negligeable
WO2009049460A1 (fr) * 2007-10-15 2009-04-23 Jiangsu Hengrui Medicine Co., Ltd. Nouveau matériau conditionné de sévoflurane
DK2244737T3 (da) * 2008-01-22 2019-07-08 Univ Texas Flygtige anæstetiske sammensætninger omfattende ekstraktionsopløsningsmidler til regional anæstesi og/eller smertelindring
US20090275785A1 (en) 2008-05-01 2009-11-05 Barry Jones Distillation Method For The Purification Of Sevoflurane And The Maintenance Of Certain Equipment That May Be Used In The Distillation Process
US8563115B2 (en) 2008-08-12 2013-10-22 Xerox Corporation Protective coatings for solid inkjet applications
US8092822B2 (en) * 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
US8283643B2 (en) * 2008-11-24 2012-10-09 Cymer, Inc. Systems and methods for drive laser beam delivery in an EUV light source
US8191992B2 (en) * 2008-12-15 2012-06-05 Xerox Corporation Protective coatings for solid inkjet applications
US9278048B2 (en) * 2009-05-06 2016-03-08 Baxter International, Inc. Pharmaceutical product and method of use
US9102604B1 (en) 2010-02-15 2015-08-11 Baxter International Inc. Methods for cleaning distilling columns
CN105193774B (zh) * 2015-09-21 2018-01-16 山东新时代药业有限公司 一种七氟烷吸入剂
CN105106182B (zh) * 2015-09-21 2017-12-29 山东新时代药业有限公司 七氟烷吸入剂
CA2952552C (fr) * 2016-11-02 2018-05-15 Central Glass Company, Limited Methode de lavage de contenant de stockage de sevoflurane et methode de stockage de sevoflurane

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2992276A (en) * 1959-05-20 1961-07-11 Du Pont Process for preparing polyfluoro alkyl compounds
US3527813A (en) * 1966-10-03 1970-09-08 Air Reduction 1,1,2 - trifluoro - 2 - chloroethyl difluoromethyl ether and its method of preparation
US3689571A (en) * 1970-07-31 1972-09-05 Baxter Laboratories Inc Fluorinated ether
GB1499818A (en) * 1974-12-06 1978-02-01 Ici Ltd Anaesthetic composition
US4469898A (en) * 1979-12-26 1984-09-04 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
US4250334A (en) * 1979-12-26 1981-02-10 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
JP2786108B2 (ja) * 1994-03-31 1998-08-13 セントラル硝子株式会社 フルオロメチル−１，１，１，３，３，３−ヘキサフルオロイソプロピルエーテルの精製方法
IT1270239B (it) * 1994-06-17 1997-04-29 Zambon Spa Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

Also Published As

Publication number Publication date
JP2005279283A (ja) 2005-10-13
AU5930098A (en) 1998-08-18
ES2170474T3 (es) 2002-08-01
CN1321958C (zh) 2007-06-20
NO993606L (no) 1999-09-24
ES2256104T3 (es) 2006-07-16
DE69833884T2 (de) 2006-08-24
NO993606D0 (no) 1999-07-23
US20040048932A1 (en) 2004-03-11
DE69833884D1 (de) 2006-05-11
DK0967975T3 (da) 2001-09-17
CA2278133C (fr) 2001-06-26
DE69800928T2 (de) 2001-11-22
JP2006143742A (ja) 2006-06-08
DE69800928D1 (de) 2001-07-19
BR9806996A (pt) 2000-03-14
US20020016373A1 (en) 2002-02-07
DK1114641T3 (da) 2006-05-15
JP2006137769A (ja) 2006-06-01
ATE201987T1 (de) 2001-06-15
JP3664648B2 (ja) 2005-06-29
HUP0002101A2 (hu) 2001-05-28
KR100368672B1 (ko) 2003-01-24
BG103656A (en) 2000-04-28
US20060148906A1 (en) 2006-07-06
CO4920220A1 (es) 2000-05-29
CN1152674C (zh) 2004-06-09
PL334477A1 (en) 2000-02-28
CA2626424A1 (fr) 1998-07-30
BG109751A (bg) 2008-06-30
EP0967975B1 (fr) 2001-06-13
PT1114641E (pt) 2006-05-31
HUP0002101A3 (en) 2002-03-28
US6444859B2 (en) 2002-09-03
HK1074434A1 (en) 2005-11-11
BG65414B1 (bg) 2008-07-31
JP3183520B2 (ja) 2001-07-09
PT967975E (pt) 2001-11-30
CA2278133A1 (fr) 1998-07-30
US20030130359A1 (en) 2003-07-10
AR057610A2 (es) 2007-12-05
EP1114641A2 (fr) 2001-07-11
US5990176A (en) 1999-11-23
CN1560003A (zh) 2005-01-05
EP0967975A1 (fr) 2000-01-05
WO1998032430A1 (fr) 1998-07-30
US6288127B1 (en) 2001-09-11
IL130150A (en) 2004-09-27
US6677492B2 (en) 2004-01-13
TR199901579T2 (xx) 1999-12-21
GR3036190T3 (en) 2001-10-31
CN1244797A (zh) 2000-02-16
CZ297092B6 (cs) 2006-09-13
CZ256199A3 (cs) 1999-11-17
AR011090A1 (es) 2000-08-02
EP1114641A3 (fr) 2003-05-28
JP2000510159A (ja) 2000-08-08
NZ335994A (en) 2000-08-25
EP1114641B1 (fr) 2006-03-22
IL130150A0 (en) 2001-03-19
JP2001187729A (ja) 2001-07-10
CN1899271A (zh) 2007-01-24
AU726733B2 (en) 2000-11-16
SK86199A3 (en) 2000-06-12
SK284243B6 (sk) 2004-12-01
ATE320798T1 (de) 2006-04-15
KR20000070482A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
ZA98418B (en) Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
HUP0100178A3 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
HUP0000065A3 (en) Olanzapine dihydrate d and pharmaceutical compositions containing the same
NZ314184A (en) Substituted quinazoline derivatives and pharmaceutical compositions
EG24118A (en) Pharmaceutical compositions
IL135177A0 (en) Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same
ZA968322B (en) Solid sillicone compositions and methods for their preparation and use
GB9615089D0 (en) Esters and compositions comprising them
EP1015014A4 (fr) Procedes et compositions pour inhiber l'angiogenese
IL129089A0 (en) New derivatives from piperidine-keto acid their preparation and use
GB9616672D0 (en) Pharmaceutical compositions
PL331423A1 (en) Muporocin and chlorohexidrin containing compositions
GB9610359D0 (en) Pharmaceutical compositions
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
ZA9811655B (en) Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same
HUP0101733A3 (en) Pharmaceutical compositions containing sulfonyl-dipeptides and their use
HUP0000460A3 (en) Imidazopyridazines and pharmaceutical compositions thereof
GB9725946D0 (en) Lipid compositions and their use
GB9622681D0 (en) Pharmaceutical compositions
GB9606429D0 (en) Pharmaceutical compositions
GB9613457D0 (en) Pharmaceutical compositions
GB9618376D0 (en) Pharmaceutical compositions
AUPO982097A0 (en) Methods and compositions for use therein
GB9610136D0 (en) Pharmaceutical compositions
GB9600431D0 (en) Esters and pharmaceutical compositions